Literature DB >> 12458899

Post-radiation angiosarcoma and bilateral mastectomy.

Debasis Adhikari1, Steven I Hajdu, David Levine.   

Abstract

We report the occurrence of bilateral angiosarcoma after radiation therapy for breast carcinoma in a 64 yr-old woman. The first angiosarcoma developed 17 yr after radiation therapy to the right breast; the second angiosarcoma developed 1.5 yr after radiation therapy to the left breast. Recognizing angiosarcoma in radiated breast tissue is essential to appropriate therapy. The role of irradiation after surgery as adjuvant therapy is to be reviewed.

Entities:  

Mesh:

Year:  2002        PMID: 12458899

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.

Authors:  Johanna Manner; Bernhard Radlwimmer; Peter Hohenberger; Katharina Mössinger; Stefan Küffer; Christian Sauer; Djeda Belharazem; Andreas Zettl; Jean-Michel Coindre; Christian Hallermann; Jörg Thomas Hartmann; Detlef Katenkamp; Kathrin Katenkamp; Patrick Schöffski; Raf Sciot; Agnieszka Wozniak; Peter Lichter; Alexander Marx; Philipp Ströbel
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

2.  Radiation-induced sarcoma of the breast: a systematic review.

Authors:  Grishma R Sheth; Lee D Cranmer; Benjamin D Smith; Lauren Grasso-Lebeau; Julie E Lang
Journal:  Oncologist       Date:  2012-02-14

3.  High-risk features in radiation-associated breast angiosarcomas.

Authors:  S P D'Angelo; C R Antonescu; D Kuk; L Qin; N Moraco; R C Carvajal; P Chi; M A Dickson; M Gounder; M L Keohan; S Singer; G K Schwartz; W D Tap
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

Review 4.  Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.

Authors:  Askin Dogan; Peter Kern; Beate Schultheis; Günther Häusler; Günther A Rezniczek; Clemens B Tempfer
Journal:  BMC Cancer       Date:  2018-04-24       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.